Merck acquires global rights for Orion's prostate cancer CYP11A1 inhibitor in a $1.6bn deal.
Merck & Co. has gained exclusive global rights to develop and commercialize Orion Corporation's opevesostat (MK-5684/ODM-208), a clinical-stage CYP11A1 inhibitor targeting prostate cancer, in a deal worth up to $1.6bn. Orion is eligible for milestone payments of up to $30m for development, $625m for regulatory milestones, and $975m in sales-based milestones. Merck will cover all development and commercialization costs, while Orion continues to manufacture clinical and commercial supply.
July 01, 2024
8 Articles